本帖最后由 老马 于 2012-1-13 21:20 编辑
5 P8 r$ s: X3 b8 I) a/ D3 X- w( e1 n
爱必妥和阿瓦斯丁的比较
6 d! m; X5 X7 C' @; j$ _# K
: A: f( Z4 e+ M' H; y
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/" Y$ A/ o; Z, ?- H! U4 ~
4 v6 k4 K5 _* l. j6 b. f: [# y
3 P% Y0 Q) U7 K1 w" K0 [0 K7 E
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
; w" ]* v( s) F& U e. n3 a==================================================
" [7 l; M. K1 \3 P0 d8 q/ g" pOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)" _8 O# J. D( F3 T1 ^( H) m) }
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.$ v& g; [1 v: I4 f/ ^
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.& S0 _7 z9 s4 l/ v7 {, L( M1 q
|